Optimal timing for intermittent administration of parathyroid hormone (1–34) for distraction osteogenesis in rabbits

Inada, Narisaku; Ohata, Tetsuya; Maruno, Hideto; Morii, Takeshi; Hosogane, Naobumi; Ichimura, Shoichi

doi:10.1186/s13018-022-03019-2

Cited by 3 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal timing of PTH (1–34) administration in DO is during the consolidation phase. Inada et al complemented that this period was primarily characterized by intramembranous ossification ( Inada et al, 2022 ). Teriparatide (rhPTH) is the active fragment of endogenous human PTH.…”

Section: Pharmacological Therapymentioning

confidence: 99%

Overview of Physical and Pharmacological Therapy in Enhancing Bone Regeneration Formation During Distraction Osteogenesis

Liu

Guo

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Distraction osteogenesis (DO) is a kind of bone regeneration technology. The principle is to incise the cortical bone and apply continuous and stable distraction force to the fractured end of the cortical bone, thereby promoting the proliferation of osteoblastic cells in the tension microenvironment and stimulating new bone formation. However, the long consolidation course of DO presumably lead to several complications such as infection, fracture, scar formation, delayed union and malunion. Therefore, it is of clinical significance to reduce the long treatment duration. The current treatment strategy to promote osteogenesis in DO includes gene, growth factor, stem-cell, physical and pharmacological therapies. Among these methods, pharmacological and physical therapies are considered as safe, economical, convenience and effective. Recently, several physical and pharmacological therapies have been demonstrated with a decent ability to enhance bone regeneration during DO. In this review, we have comprehensively summarized the latest evidence for physical (Photonic, Waves, Gas, Mechanical, Electrical and Electromagnetic stimulation) and pharmacological (Bisphosphonates, Hormone, Metal compounds, Biologics, Chinese medicine, etc) therapies in DO. These evidences will bring novel and significant information for the bone healing during DO in the future.

show abstract

Section: Pharmacological Therapymentioning

confidence: 99%

Overview of Physical and Pharmacological Therapy in Enhancing Bone Regeneration Formation During Distraction Osteogenesis

Liu

Guo

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

The effect of intermittent parathyroid hormone on bone lengthening: current evidence to inform future effective interventions

Kitcharanant

Chattipakorn

2023

Osteoporos Int

View full text Add to dashboard Cite

The effects of SDF-1 combined application with VEGF on femoral distraction osteogenesis in rats

Fu,

Li,

Yang

et al. 2024

Open Life Sciences

View full text Add to dashboard Cite

Bone regeneration and mineralization can be achieved by means of distraction osteogenesis (DO). In the present study, we investigated the effect of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) on the new bone formation during DO in rats. Forty-eight Sprague–Dawley rats were randomized into four groups of 12 rats each. We established the left femoral DO model in rats and performed a mid-femoral osteotomy, which was fixed with an external fixator. DO was performed at 0.25 mm/12 h after an incubation period of 5 days. Distraction was continued for 10 days, resulting in a total of 5 mm of lengthening. After distraction, the solution was locally injected into the osteotomy site, once a day 1 ml for 1 week. One group received the solvent alone and served as the control, and the other three groups were treated with SDF-1, VEGF, and SDF-1with VEGF in an aqueous. Sequential X-ray radiographs were taken two weekly. The regeneration was monitored with the use of micro-CT analysis, mechanical testing, and histology. Radiographs showed accelerated regenerate ossification in the SDF-1, VEGF, and SDF-1 with the VEGF group, with a larger amount of new bone compared with the control group, especially SDF-1 with the VEGF group. Micro-CT analysis and biomechanical tests showed Continuous injection of the SDF-1, VEGF, and SDF-1 with VEGF during the consolidation period significantly increased bone mineral density bone volume, mechanical maximum loading, and bone mineralization of the regenerate. Similarly, the expression of osteogenic-specific genes, as determined by real-time polymerase chain reaction , was significantly higher in SDF-1 with the VEGF group than in the other groups. Histological examination revealed more new trabeculae in the distraction gap and more mature bone tissue for the SDF-1 with the VEGF group. SDF-1 and VEGF promote bone regeneration and mineralization during DO, and there is a synergistic effect between the SDF-1 and VEGF. It is possible to provide a new and feasible method to shorten the period of treatment of DO.

show abstract

Optimal timing for intermittent administration of parathyroid hormone (1–34) for distraction osteogenesis in rabbits

Cited by 3 publications

References 59 publications

Overview of Physical and Pharmacological Therapy in Enhancing Bone Regeneration Formation During Distraction Osteogenesis

Overview of Physical and Pharmacological Therapy in Enhancing Bone Regeneration Formation During Distraction Osteogenesis

The effect of intermittent parathyroid hormone on bone lengthening: current evidence to inform future effective interventions

The effects of SDF-1 combined application with VEGF on femoral distraction osteogenesis in rats

Contact Info

Product

Resources

About